复方苦参注射液联合双膦酸盐类药物治疗恶性肿瘤骨转移所致癌性疼痛患者的疗效和安全性Meta分析  

Meta-Analysis of Efficacy and Safety of Compound Kushen Injection Combined with Bisphosphonates in the Treatment of Cancer Pain due to Bone Metastasis of Malignant Tumor

作　　者：李知非[1] 左诗淳 唐静 LI Zhi-fei;ZUO Shi-chun;TANG Jing(Department of Oncology,Jinan Hospital of Traditional Chinese Medicine,Jinan 250012,China)

机构地区：[1]济南市中医医院肿瘤科,济南250012

出　　处：《中国合理用药探索》2024年第6期40-49,共10页Chinese Journal of Rational Drug Use

摘　　要：目的:系统评价复方苦参注射液(CKI)联合双膦酸盐(BPs)类药物治疗恶性肿瘤骨转移所致癌性疼痛(以下简称癌痛)患者的有效性和安全性。方法:计算机检索中国知网(CNKI)、万方数据库(Wanfang)、维普中文科技期刊数据库(VIP)、PubMed、CochraneLibrary,检索时间均为建库至2024年1月22日,收集CKI联合BPs类药物治疗恶性肿瘤骨转移所致癌痛患者的随机对照试验(RCT)研究文献。通过Cochrane风险评估工具进行文献质量评价,并采用RevMan5.4软件进行Meta分析。结果:共检索出245篇文献,最终纳入27篇文献,共计2255例患者,其中对照组(单用BPs类药物)1108例,联合组(CKI联合BPs类药物)1147例。Meta分析结果显示,在疼痛缓解率、生活质量评分[卡诺夫斯凯计分(KPS)]、血清碱性磷酸酶(ALP)和不良反应发生率方面,CKI联合BPs类药物的治疗效果均优于单用BPs类药物(P<0.01)。结论:CKI联合BPs类药物治疗可有效提高恶性肿瘤骨转移所致癌痛患者的疼痛缓解率、KPS评分,改善血清ALP水平,降低不良事件的发生风险。Objective:To systematically evaluate the efficacy and safety of compound Kushen injection(CKI)combined with bisphosphonates(BPs)in the treatment of cancer pain due to bone metastasis of malignant tumor.Methods:Databases,including CNKI,Wanfang,VIP,PubMed and Cochrane Library,were systematically searched starting from the database establishment to 22 January 2024.Randomized controlled trials(RCTs)of CKI combined with BPs in the treatment of cancer pain due to bone metastasis of malignant tumor were collected,their quality was evaluated by Cochrane tool for risk assessment,and Meta-analysis was performed using RevMan 5.4 software.Results:A total of 245 articles were retrieved,and finally 27 articles were included,with a total of 2255 patients,including 1108 patients in the control group(BPs alone)and 1147 patients in the combination group(CKI combined with BPs).The results of Meta-analysis showed that the efficacy of CKI combined with BPs was superior to that of BPs alone in terms of pain relief rate,quality of life score[(Karnofsky performance score(KPS)],serum alkaline phosphatase(ALP)and incidence of adverse reactions(P<0.01).Conclusion:CKI combined with BPs can effectively improve the pain relief rate,KPS score,serum ALP level and reduce the incidence of adverse events in patients with cancer pain due to bone metastasis of malignant tumor.

关 键 词：复方苦参注射液 骨转移 疼痛 双膦酸盐 META分析 

分 类 号：R730.5[医药卫生—肿瘤]